CN103826653A - 免疫接种和诊断应用中的多瘤病毒jc肽和蛋白质 - Google Patents
免疫接种和诊断应用中的多瘤病毒jc肽和蛋白质 Download PDFInfo
- Publication number
- CN103826653A CN103826653A CN201280041815.3A CN201280041815A CN103826653A CN 103826653 A CN103826653 A CN 103826653A CN 201280041815 A CN201280041815 A CN 201280041815A CN 103826653 A CN103826653 A CN 103826653A
- Authority
- CN
- China
- Prior art keywords
- protein
- jcv
- pml
- cells
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11006031A EP2548567A1 (en) | 2011-07-22 | 2011-07-22 | Polyoma virus JC peptides and proteins in vaccination and diagnostic applications |
| EP11006031.6 | 2011-07-22 | ||
| PCT/EP2012/064445 WO2013014134A2 (en) | 2011-07-22 | 2012-07-23 | Polyoma virus jc peptides and proteins in vaccination and diagnostic applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103826653A true CN103826653A (zh) | 2014-05-28 |
Family
ID=46548481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280041815.3A Pending CN103826653A (zh) | 2011-07-22 | 2012-07-23 | 免疫接种和诊断应用中的多瘤病毒jc肽和蛋白质 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9738690B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2548567A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014520877A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140062702A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103826653A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012288955B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014001516A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2842543A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201490322A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1198517A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2014000776A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013014134A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022100459A1 (zh) * | 2020-11-16 | 2022-05-19 | 艾棣维欣(苏州)生物制药有限公司 | 一种预防和治疗默克尔细胞癌的新型疫苗 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150065367A1 (en) * | 2011-12-12 | 2015-03-05 | Janssen Diagnostics Bvba | Polyomavirus peptide sequences |
| US10300116B2 (en) | 2013-06-10 | 2019-05-28 | Ansun Biopharma, Inc. | Treatment for BK polyomavirus infection |
| US9931393B2 (en) | 2013-12-20 | 2018-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic JC polyomavirus compositions and methods of use |
| EP2926831A1 (en) * | 2014-03-31 | 2015-10-07 | Ruprecht-Karls-Universität Heidelberg | CD8+ T-cell epitopes from polyomavirus capsid protein VP1 for vaccination |
| WO2016073595A1 (en) * | 2014-11-05 | 2016-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | T cells and dendritic cells for polyomavirus therapy |
| WO2016104046A1 (ja) * | 2014-12-22 | 2016-06-30 | 日東電工株式会社 | 透明導電性フィルム |
| IT201600083859A1 (it) * | 2016-08-09 | 2018-02-09 | Univ Degli Studi Di Ferrara | Immunosaggio per l’identificazione di anticorpi contro il virus Polioma JC (JCPyV) mediante l’uso di peptidi sintetici. |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010000182A1 (zh) * | 2008-06-30 | 2010-01-07 | 腾讯科技(深圳)有限公司 | 一种关键词内容发布方法及系统 |
| WO2010100182A1 (en) * | 2009-03-03 | 2010-09-10 | Assistance Publique - Hopitaux De Paris | Immunological method for detecting active jcv infection |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3767755B2 (ja) | 1995-06-23 | 2006-04-19 | エーザイ株式会社 | 抗jcウイルス抗体 |
| DE19543553B4 (de) | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| DE10131145B4 (de) | 2001-06-28 | 2005-07-14 | Innovent E.V. | Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen |
| JP4840792B2 (ja) | 2001-11-22 | 2011-12-21 | 独立行政法人科学技術振興機構 | JCウイルスagnoを対象としたPMLの治療 |
| AU2003238008A1 (en) | 2002-06-12 | 2003-12-31 | Temple University Of The Commonwealth System Of Higher Education | Method of cell growth inhibition with agnoprotein |
| JP2005341864A (ja) | 2004-06-02 | 2005-12-15 | Japan Science & Technology Agency | Jcウイルスの粒子形成阻害剤 |
| US7468186B2 (en) * | 2005-07-22 | 2008-12-23 | City Of Hope | Polyomavirus cellular epitopes and uses therefor |
| US20080057079A1 (en) | 2006-08-31 | 2008-03-06 | Baylor Research Institute | JC Virus Vaccine |
| AU2010210979B2 (en) * | 2009-02-05 | 2015-12-10 | Biogen Ma Inc. | Methods for the detection of JC polyoma virus |
| WO2010099205A1 (en) | 2009-02-24 | 2010-09-02 | The Trustees Of The University Of Pennsylvania | Methods for treating progressive multifocal leukoencephalopathy (pml) |
| WO2011124652A1 (en) * | 2010-04-08 | 2011-10-13 | Fondazione Centro San Raffaele Del Monte Tabor | Immunodominant peptide of polyomavirus jc and uses thereof |
-
2011
- 2011-07-22 EP EP11006031A patent/EP2548567A1/en not_active Withdrawn
-
2012
- 2012-07-23 EP EP12737822.2A patent/EP2734218A2/en not_active Withdrawn
- 2012-07-23 EA EA201490322A patent/EA201490322A1/ru unknown
- 2012-07-23 KR KR1020147004608A patent/KR20140062702A/ko not_active Withdrawn
- 2012-07-23 US US14/234,065 patent/US9738690B2/en not_active Expired - Fee Related
- 2012-07-23 WO PCT/EP2012/064445 patent/WO2013014134A2/en not_active Ceased
- 2012-07-23 JP JP2014520691A patent/JP2014520877A/ja active Pending
- 2012-07-23 MX MX2014000776A patent/MX2014000776A/es unknown
- 2012-07-23 HK HK14112523.5A patent/HK1198517A1/xx unknown
- 2012-07-23 CN CN201280041815.3A patent/CN103826653A/zh active Pending
- 2012-07-23 AU AU2012288955A patent/AU2012288955B2/en not_active Expired - Fee Related
- 2012-07-23 CA CA2842543A patent/CA2842543A1/en not_active Abandoned
- 2012-07-23 BR BR112014001516A patent/BR112014001516A2/pt not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010000182A1 (zh) * | 2008-06-30 | 2010-01-07 | 腾讯科技(深圳)有限公司 | 一种关键词内容发布方法及系统 |
| WO2010100182A1 (en) * | 2009-03-03 | 2010-09-10 | Assistance Publique - Hopitaux De Paris | Immunological method for detecting active jcv infection |
Non-Patent Citations (3)
| Title |
|---|
| DU PASQUIER R.A.等: "Low Frequency of Cytotoxic T Lymphocytes against the Novel HLA-A*0201-Restricted JC Virus Epitope VP1p36 in Patients with Proven or Possible Progressive Multifocal Leukoencephalopathy", 《JOURNAL OF VIROLOGY》 * |
| GOLDMANN C.等: "Molecular Cloning and Expression of Major Structural Protein VP1 of the Human Polyomavirus JC Virus: Formation of Virus-Like Particles Useful for Immunological and Therapeutic Studies", 《JOURNAL OF VIROLOGY》 * |
| KORALNIK I.J.等: "Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope", 《JOURNAL OF IMMUNOLOGY》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022100459A1 (zh) * | 2020-11-16 | 2022-05-19 | 艾棣维欣(苏州)生物制药有限公司 | 一种预防和治疗默克尔细胞癌的新型疫苗 |
| US12691168B2 (en) | 2020-11-16 | 2026-07-28 | Advaccine (Suzhou) Biopharmaceuticals Co. Ltd. | Vaccine for preventing and treating Merkel cell carcinoma |
Also Published As
| Publication number | Publication date |
|---|---|
| US9738690B2 (en) | 2017-08-22 |
| MX2014000776A (es) | 2014-11-26 |
| CA2842543A1 (en) | 2013-01-31 |
| KR20140062702A (ko) | 2014-05-26 |
| AU2012288955B2 (en) | 2017-06-08 |
| WO2013014134A2 (en) | 2013-01-31 |
| WO2013014134A3 (en) | 2013-05-02 |
| JP2014520877A (ja) | 2014-08-25 |
| BR112014001516A2 (pt) | 2017-02-14 |
| AU2012288955A1 (en) | 2014-02-20 |
| EP2548567A1 (en) | 2013-01-23 |
| HK1198517A1 (en) | 2015-05-15 |
| EP2734218A2 (en) | 2014-05-28 |
| NZ620196A (en) | 2016-10-28 |
| US20140356320A1 (en) | 2014-12-04 |
| EA201490322A1 (ru) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9738690B2 (en) | Polyoma virus JC peptides and proteins in vaccination and diagnostic applications | |
| Nozuma et al. | Human T-lymphotropic virus type 1 (HTLV-1) and cellular immune response in HTLV-1-associated myelopathy/tropical spastic paraparesis | |
| Lannes et al. | Interactions of human microglia cells with Japanese encephalitis virus | |
| Matsuura et al. | Neuroimmunity of HTLV-I infection | |
| Moffat et al. | Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells | |
| JP2023021131A (ja) | 免疫を調節するペプチド、ポリペプチド又は細胞を作製する方法 | |
| Ersching et al. | A human trypanosome suppresses CD8+ T cell priming by dendritic cells through the induction of immune regulatory CD4+ Foxp3+ T cells | |
| Lü et al. | Effects of autoimmunity on recovery of function in adult rats following spinal cord injury | |
| Mohindru et al. | Initial capsid‐specific CD4+ T cell responses protect against Theiler's murine encephalomyelitisvirus‐induced demyelinating disease | |
| Rose et al. | Pathogenesis of multiple sclerosis | |
| US20240325441A1 (en) | Modified immune cell and use thereof | |
| US20230036213A1 (en) | T-cell epitopes of human parainfluenza virus 3 for adoptive t-cell immunotherapy | |
| Donaldson et al. | Role of Epstein-Barr virus in multiple sclerosis | |
| WO2021062039A2 (en) | T-cell compositions and methods of making and using the same | |
| WO2012001099A1 (en) | Enterovirus vaccines for preventing and treating type 1 diabetes (ii) | |
| EP2926831A1 (en) | CD8+ T-cell epitopes from polyomavirus capsid protein VP1 for vaccination | |
| Ghezzi | UNRAVELLING THE ROLE OF MUCOSAL ASSOCIATED INVARIANT T CELLS IN THE PATHOGENESIS OF MULTIPLE SCLEROSIS AND ITS ANIMAL MODEL | |
| Cioni | Characterizing Determinants of BK Polyomavirus-specific Immune Response | |
| NZ620196B2 (en) | Polyoma virus jc peptides and proteins in vaccination and diagnostic applications | |
| Mockus | Immune-mediated antiviral defense against polyomavirus infection of the brain | |
| CN119490580A (zh) | 一种t细胞抗原受体及其制备方法和应用 | |
| Mohindru | CD4+ T cell response in the central nervous system in a virus model of multiple sclerosis | |
| Lowther | Regulatory and Effector Immune Cells in a Spontaneous Multiple Sclerosis Model | |
| HK40013538B (en) | Methods to produce peptides, polypeptides or cells for modulating immunity | |
| HK40013538A (en) | Methods to produce peptides, polypeptides or cells for modulating immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140528 |